Neuromodulation of Sleep and Mood: A Multimodal Biomarker Study of Non-Invasive Vagal Nerve Stimulation (MOSAIC-VNS) (MOSAIC-VNS)
The purpose of this study is to learn how non-invasive cervical transcutaneous vagus nerve stimulation (ctVNS) - a treatment given by holding a small hand-held device against the right part of your neck (cervical vagus nerve) - affects sleep, heart rhythm, mood, and certain markers in the blood and some genetic material.
The main questions it aims to answer are:
- Will ctVNS enhance both subjective and objective sleep continuity and regularity, improve circadian stability, and increase parasympathetic HRV indices compared with the end-of-sham baseline?
- Will improvements in HRV and sleep be associated with greater improvement in standardized depression ratings, with treatment effects mediated in part by improvements in sleep and in part by sleep-independent autonomic mechanisms?
- Will ctVNS modify the expression of miRNAs related to sleep, stress, inflammation, and neuroplasticity, and baseline or early-change miRNA profiles, combined with physiological data, and may help distinguish responders from non-responders?
This study lasts about 7 weeks.
Participants will be asked to do the following:
Visit 1/ Baseline (in person):
- Participants will answer questions about their health, mood, and sleep;
- have their blood pressure and pulse taken;
- give about 28 mL (about 6 teaspoons) of blood - 20 mL for the research measurements and 8 mL for routine safety blood tests;
- be fitted with a wrist device that measures your heart rate, physical activity and sleep; and be given the study device with training on how to use it at home.
This visit will last about 2 hours.
Weeks 1-6 (at home):
- Participants will use the study device (nerve stimulator) twice a day (morning within 1 hour of waking, and evening within 1 hour of your usual bedtime), each use lasting about 2 minutes;
- Participants will also need to wear the wrist device day and night;
- Participants will fill out a short sleep diary each morning.
Visit 2/ Week 2 (in person) and Visit 3/ Week 6 (in person):
- Participants will repeat the questionnaires and interviews from Visit 1;
- have their blood pressure and pulse taken;
- give another blood sample of about 20 mL;
- have the data from their wrist device downloaded.
- At each in-person visit after visit 1, their study device will be checked and may be exchanged for another device.
This visit will last about 1.5 - 2 hours.
The investigators will call participants on the phone to check-in at Weeks 1, 3, and 5, and a safety call at Week 7. These phone calls will last about 15 minutes.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Major depressive disorder (MDD) and insomnia are highly prevalent, frequently co-occur, and rank among the leading causes of disability worldwide. Up to 80% of people with MDD report significant sleep disturbance, and persistent insomnia predicts higher relapse, poorer treatment response, and greater functional impairment. Autonomic dysregulation, commonly indexed by reduced heart rate variability (HRV), is a shared feature of both conditions and a marker of poor outcome [1], alongside circadian disruption and neuroinflammatory signaling.
Cervical transcutaneous vagus nerve stimulation (ctVNS) engages vagal afferents transcutaneously and may rebalance sympathetic-parasympathetic tone [2,3] and attenuate neuroinflammatory signaling implicated in anxiety and depression [4], with downstream effects on emotion-regulatory circuits and on sleep. Despite this mechanistic plausibility, treatment response to ctVNS remains heterogeneous and mechanistically unclear, and no validated marker identifies who will benefit.
Circulating microRNAs (miRNAs) are stable, accessible post-transcriptional regulators whose peripheral profiles are altered in MDD and may track with diagnosis or relapse risk [5,6]. Preclinical evidence shows that vagus nerve stimulation, which engages the same afferent pathways as ctVNS, modulates stress- and neuroplasticity-related miRNAs (for example, miR-183-3p) [7-9]. Neural-derived exosomes (NDE) isolated from plasma are enriched for signals of neuronal origin and provide a means of interrogating brain-relevant molecular processes from a peripheral blood sample.
Neuromodulation is changing how mental and other central nervous system disorders are treated, but its clinical use is limited by an inability to predict who will respond or why. Three specific gaps slow progress: (1) the pathways linking ctVNS to improvements in sleep and depression remain unclear; (2) no study has combined continuous wearable monitoring with circulating candidate biomarkers to predict response; and (3) the relationship between autonomic change and depression improvement has not been defined.
This study addresses those gaps by combining longitudinal wearable-derived autonomic monitoring, subjective and objective sleep phenotyping, standardized clinical outcomes, and circulating neural-derived exosomal miRNA profiling within a single mechanistic framework. The design separates sleep-mediated from sleep-independent autonomic pathways underlying changes in depression.
A within-subject sham run-in was selected rather than a parallel randomized design because the aim of this pilot is within-subject signal detection and effect-size estimation rather than controlled efficacy testing. The sham run-in establishes a stable, expectancy-adjusted personal baseline and prevents carryover from active stimulation from contaminating that reference. A fixed sham-to-active order partially confounds treatment with time; this limitation is stated explicitly, is mitigated by the end-of-sham anchor and by a group-level autonomic target-engagement check, and is addressed in the planned subsequent randomized, concurrent sham-controlled trial.
Healthy reference participants (Cohort B) are enrolled not as efficacy subjects but to establish normative ranges for HRV, sleep metrics, and candidate miRNA expression, enabling interpretation of disease-related biomarker deviations.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Samantha White
- 電話番号:205-934-9189
- メール:swwhite@uabmc.edu
研究連絡先のバックアップ
- 名前:Kristine Pike
- 電話番号:205-975-8542
- メール:kristinepike@uabmc.edu
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- University of Alabama at Birmingham (UAB)
-
主任研究者:
- Matthew Macaluso, DO
-
コンタクト:
- Kristine Pike
- 電話番号:205-975-8542
- メール:kristinepike@uabmc.edu
-
コンタクト:
- Samantha White
- 電話番号:2059349189
- メール:swwhite@uabmc.edu
-
副調査官:
- Justin Thomas, PhD
-
副調査官:
- Yogesh Dwivedi, PhD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
To be eligible, participants must meet all of the following criteria:
-
Adults aged 18 through 50 years, inclusive, at the time of consent.
-
Able to understand and provide written informed consent in English.
-
Willing and able to wear a study-provided wrist-worn device continuously for approximately 6 weeks and to complete daily sleep diaries.
-
Willing and able to self-administer the study device twice daily for 6 weeks and to complete a device use log.
-
Access to a smartphone compatible with the study wearable platform, or willingness to use a study-provided device.
-
Regular sleep opportunity of at least 6 hours per 24-hour period.
Cohort A (symptomatic) - additional inclusion criteria:
-
Insomnia Severity Index (ISI) total score ≥ 15 at screening and confirmed at Visit 1.
-
MADRS total score ≥ 20 at screening and confirmed at Visit 1.
-
Meets DSM-5-TR criteria for insomnia disorder on structured clinical interview.
-
If receiving psychotropic medication or psychotherapy, the regimen has been stable for at least 6 weeks before Visit 1, and the participant and treating clinician agree it will remain stable through Visit 3.
Cohort B (healthy reference) - additional inclusion criteria:
-
ISI total score ≤ 7 and MADRS total score ≤ 8 at screening and confirmed at Visit 1.
-
No current psychiatric disorder or sleep disorder as established by structured diagnostic interview.
-
No psychotropic medication use within the prior 30 days.
-
Exclusion Criteria:
-
Participants meeting any of the following criteria are not eligible:
- Night-shift or rotating-shift work within the 30 days before Visit 1, or planned during participation.
- Travel across more than two time zones within the 14 days before Visit 1, or planned during participation.
- Any contraindication to cervical nVNS, including an implanted cervical electrical or metallic device, cardiac pacemaker or implantable cardioverter-defibrillator, any other implanted electronic device, clinically significant carotid atherosclerosis, prior cervical vagotomy, carotid endarterectomy, or cervical surgery at the application site.
- Open wound, skin breakdown, active infection, or a dermatologic condition at the intended application site.
- Known or suspected pregnancy, or breastfeeding. Participants of childbearing potential will undergo urine pregnancy testing at screening..
- Clinically significant cardiac arrhythmia, uncontrolled hypertension (systolic ≥ 160 or diastolic ≥ 100 mmHg on repeated measurement), congestive heart failure, or syncope of unclear cause.
- Untreated moderate-to-severe obstructive sleep apnea (STOP-Bang ≥ 5 without evaluation and clearance), restless legs syndrome requiring pharmacologic treatment, narcolepsy, or a circadian rhythm sleep-wake disorder.
- Moderate or severe substance or alcohol use disorder within the prior 6 months, or a positive urine drug screen for a non-prescribed substance judged to affect sleep or autonomic measures.
- Lifetime diagnosis of bipolar I disorder, schizophrenia, schizoaffective disorder, or another primary psychotic disorder.
- Active suicidal ideation with intent or plan (C-SSRS ideation type 4 or 5), any suicide attempt within the prior 6 months, or any clinical presentation requiring urgent or higher-level psychiatric care.
- Use of an alternative neuromodulation therapy (implanted VNS, transcranial magnetic stimulation, transcranial direct current stimulation, or electroconvulsive therapy) within the prior 3 months.
- Initiation of, or change in dose of, any medication with known substantial effects on heart rate variability (for example, beta-blockers, anticholinergics) within 6 weeks before Visit 1.
- Any medical, neurological, or psychiatric condition that, in the investigator's judgment, would compromise participant safety, adherence, or interpretation of study measures.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:非ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
偽コンパレータ:Sham Run-In (Weeks 1-2)
Inactive sham stimulation, twice daily. Each participant receives first. |
sham run-in ctVNS |
|
アクティブコンパレータ:Active stimulation (Weeks 3-6)
Blinded active cervical nVNS, twice daily. Each participant receives second. |
ctVNS |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Primary physiologic endpoint as change in parasympathetic heart rate variability (nocturnal RMSSD).
時間枠:Change from Visit 2 (week 2) to Visit 3 (week 6).
|
Linear mixed-effects models estimating within-subject physiologic change from the end-of-sham anchor (week 2), with participant as a random effect and phase, time, cohort, age, sex, and body mass index as fixed effects. |
Change from Visit 2 (week 2) to Visit 3 (week 6).
|
|
Primary clinical endpoint as change in Insomnia Sleep Index (ISI) total score in Cohort A (affected).
時間枠:Change from Visit 2 (week 2) to Visit 3 (week 6).
|
The ISI is a 7-item self-report questionnaire used to assess nature, severity and impact of insomnia over previous 2 weeks. Each item is rated 0-4 , with total score range of 0-28. Higher score indicates greater insomnia severity. Response is defined as ≥ 50% reduction in ISI total score or remission (ISI ≤ 7). |
Change from Visit 2 (week 2) to Visit 3 (week 6).
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score in Cohort A (affected) from Visit 2 to Visit 3.
時間枠:Change from Visit 2 (week 2) to Visit 3 (week 6).
|
The MADRS is a 10-item clinician rated scale used to assess severity of depression symptoms. Each item is scored from 0 to 6, with total possible score range of 0-60. A total score of 0-8 indicates no depression, and 8 or above would indicate some level of depression ranging from mild to severe. Higher score indicates greater depression symptoms. |
Change from Visit 2 (week 2) to Visit 3 (week 6).
|
|
Differential expression of neural-derived exosomal microRNAs from Visit 2 to Visit 3.
時間枠:Change from Visit 2 (week 2) to Visit 3 (week 6).
|
Differential expression screening with Benjamini-Hochberg false discovery rate control (q < 0.05), followed by exploratory penalized regression classifiers with nested cross-validation and reporting of optimism-corrected performance. |
Change from Visit 2 (week 2) to Visit 3 (week 6).
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Matthew Macaluso, DO、University of Alabama at Birmingham
出版物と役立つリンク
一般刊行物
- Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016 Jun;25(3):1057-73. doi: 10.1177/0962280215588241. Epub 2015 Jun 19.
- Tiwari R, Kumar R, Malik S, Raj T, Kumar P. Analysis of Heart Rate Variability and Implication of Different Factors on Heart Rate Variability. Curr Cardiol Rev. 2021;17(5):e160721189770. doi: 10.2174/1573403X16999201231203854.
- Guo B, Zhang M, Hao W, Wang Y, Zhang T, Liu C. Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression. Transl Psychiatry. 2023 Jan 9;13(1):5. doi: 10.1038/s41398-022-02297-y.
- Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287-291. doi:10.1002/pst.185
- Ouyang S, Chen W, Zeng G, Lei C, Tian G, Zhu M, Liu Y, Yang M. MicroRNA-183-3p up-regulated by vagus nerve stimulation mitigates chronic systolic heart failure via the reduction of BNIP3L-mediated autophagy. Gene. 2020 Feb 5;726:144136. doi: 10.1016/j.gene.2019.144136. Epub 2019 Oct 17.
- Xuan Y, Liu S, Li Y, Dong J, Luo J, Liu T, Jin Y, Sun Z. Short-term vagus nerve stimulation reduces myocardial apoptosis by downregulating microRNA-205 in rats with chronic heart failure. Mol Med Rep. 2017 Nov;16(5):5847-5854. doi: 10.3892/mmr.2017.7344. Epub 2017 Aug 23.
- Bie B, Wang Z, Chen Y, Sheng L, Li H, You H, Ye J, Zhang Q, Li J. Vagus nerve stimulation affects inflammatory response and anti-apoptosis reactions via regulating miR-210 in epilepsy rat model. Neuroreport. 2021 Jun 9;32(9):783-791. doi: 10.1097/WNR.0000000000001655.
- Zhang HP, Liu XL, Chen JJ, Cheng K, Bai SJ, Zheng P, Zhou CJ, Wang W, Wang HY, Zhong LM, Xie P. Circulating microRNA 134 sheds light on the diagnosis of major depressive disorder. Transl Psychiatry. 2020 Mar 16;10(1):95. doi: 10.1038/s41398-020-0773-2.
- Li QS, Galbraith D, Morrison RL, Trivedi MH, Drevets WC. Circulating microRNA associated with future relapse status in major depressive disorder. Front Psychiatry. 2022 Aug 17;13:937360. doi: 10.3389/fpsyt.2022.937360. eCollection 2022.
- Lai Y, Zhou X, Guo F, Jin X, Meng G, Zhou L, Chen H, Liu Z, Yu L, Jiang H. Non-invasive transcutaneous vagal nerve stimulation improves myocardial performance in doxorubicin-induced cardiotoxicity. Cardiovasc Res. 2022 Jun 22;118(7):1821-1834. doi: 10.1093/cvr/cvab209.
- Altinkaya Z, Ozturk L, Buyukguduk I, Yanik H, Yilmaz DD, Yar B, Degirmenci E, Dal U, Veldhuizen MG. Non-invasive vagus nerve stimulation in a hungry state decreases heart rate variability. Physiol Behav. 2023 Jan 1;258:114016. doi: 10.1016/j.physbeh.2022.114016. Epub 2022 Nov 2.
- Yoshino Y, Roy B, Dwivedi Y. Differential and unique patterns of synaptic miRNA expression in dorsolateral prefrontal cortex of depressed subjects. Neuropsychopharmacology. 2021 Apr;46(5):900-910. doi: 10.1038/s41386-020-00861-y. Epub 2020 Sep 12.
- Ochi S, Roy B, Prall K, Shelton RC, Dwivedi Y. Strong associations of telomere length and mitochondrial copy number with suicidality and abuse history in adolescent depressed individuals. Mol Psychiatry. 2023 Sep;28(9):3920-3929. doi: 10.1038/s41380-023-02263-0. Epub 2023 Sep 21.
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- STUDY00000060
- TEAMSCI9617 (その他の助成金/資金番号:UAB Heersink School of Medicine (Team Science Award))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。